Skip to content
Menu

MetaVia To Report Data From Its Phase 1 Clinical Study Of DA-1726 At Precision Liver Symposium 2026

Benzinga Newsdesk 3 weeks ago

News

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from the Phase 1 clinical trial of DA-1726, a

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from the Phase 1 clinical trial of DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors, has been accepted for an oral presentation at the Precision Liver Symposium 2026, taking place November 4, 2026, in Denver, Colorado.

Read at benzinga.com